SEC Separation of ADC Brentuximab Vedotin - IDEX Health & ScienceIDEX Health & Science


    The views, information, or opinions expressed in the Industry News RSS feed belong solely to the author and do not necessarily represent those of IDEX Health & Science and its employees.

    SEC Separation of ADC Brentuximab Vedotin

    Article obtained from LCGC Liquid Chromatography (LC/HPLC) RSS Feed.

    The antibody-drug conjugate was separated from its aggregates and fragments in only one run using a YMC-SEC MAB column and varying mobile phases.

    Apr, 30 2021 |

    IDEX Health & Science is the global authority in fluidics and optics, bringing to life advanced optofluidic technologies with our products, people, and engineering expertise. Intelligent solutions for life.